Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines
- PMID: 22843987
- DOI: 10.1136/bjophthalmol-2011-301470
Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines
Abstract
Background: Deregulation of Bcl2 pathway is implicated in the pathogenesis of uveal melanoma (UM). Oncolytic adenovirus H101 is the world's first oncolytic viral therapy for cancer approved for clinical use. We aimed to explore a potential synergy of downregulating Bcl2 pathway using a small interfering RNA (siBCL2) combined with H101 therapy on UM cell lines.
Methods: The sensitivity to adenovirus infection was analysed by flow cytometry. PCR, real-time-PCR and western blot were used to detect Bcl2, p53, Bax and fibre expression. Appropriate multiplicity of H101 infection and cell survival rate were measured by a cell counting kit-8 assay. UM cells were stained with Annexin-V and propidium iodide for apoptosis assay and cell cycle distribution.
Results: VUP cells (without elevation of Bcl2) exhibited greater sensitivity to adenovirus infection than OM431 cells (Bcl2 elevated cell line). Bcl2 expression was markedly reduced by siBCL2 or siBCL2 plus H101. Combined treatment with siBCL2 and H101 produced substantial growth inhibition of OM431 cells by enhancing apoptosis and cell cycle arrest through Bax-p53-induced apoptotic pathway.
Conclusions: SiBCL2 and H101 exhibited synergistic cytotoxic effect in Bcl2 elevated UM cell lines and could potentially serve as a novel targeted molecular therapy for UM.
Similar articles
-
The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.J Cell Biochem. 2019 Apr;120(4):5766-5776. doi: 10.1002/jcb.27863. Epub 2018 Oct 15. J Cell Biochem. 2019. PMID: 30320917
-
Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.Invest Ophthalmol Vis Sci. 2010 May;51(5):2626-35. doi: 10.1167/iovs.09-3516. Epub 2009 Dec 10. Invest Ophthalmol Vis Sci. 2010. PMID: 20007825
-
Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.Mol Ther. 2009 Jan;17(1):57-64. doi: 10.1038/mt.2008.236. Epub 2008 Nov 18. Mol Ther. 2009. PMID: 19018252 Free PMC article.
-
Virus combinations and chemotherapy for the treatment of human cancers.Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Curr Opin Mol Ther. 2008. PMID: 18683102 Review.
-
Clinical trials with oncolytic adenovirus in China.Curr Cancer Drug Targets. 2007 Mar;7(2):141-8. doi: 10.2174/156800907780058817. Curr Cancer Drug Targets. 2007. PMID: 17346105 Review.
Cited by
-
ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report.Am J Ophthalmol Case Rep. 2020 Jan 31;17:100615. doi: 10.1016/j.ajoc.2020.100615. eCollection 2020 Mar. Am J Ophthalmol Case Rep. 2020. PMID: 32072076 Free PMC article.
-
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.Tumour Biol. 2014 Feb;35(2):1169-75. doi: 10.1007/s13277-013-1156-6. Epub 2013 Sep 7. Tumour Biol. 2014. PMID: 24014050
-
Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors.PLoS One. 2012;7(8):e44301. doi: 10.1371/journal.pone.0044301. Epub 2012 Aug 28. PLoS One. 2012. PMID: 22937170 Free PMC article.
-
The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.Transl Cancer Res. 2021 Oct;10(10):4290-4302. doi: 10.21037/tcr-21-905. Transl Cancer Res. 2021. PMID: 35116288 Free PMC article.
-
Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.J Invest Dermatol. 2013 Nov;133(11):2576-2584. doi: 10.1038/jid.2013.191. Epub 2013 Apr 19. J Invest Dermatol. 2013. PMID: 23604101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous